RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

被引：0
|
作者：
Chunyue Wang
Zhenlong Zhang
Yulan Sun
Song Wang
Mengmeng Wu
Qiuxiang Ou
Yang Xu
Zhiming Chen
Yang Shao
Hong Liu
Peifeng Hou
机构：
[1] Xiamen University,Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine
[2] Shengli Clinical Medical College of Fujian Medical University,Department of Thoracic Surgery
[3] Fujian Provincial Hospital,Department of Internal Medicine Division
[4] Shandong Cancer Hospital Affiliated to Shandong First Medical University,Department of Radiation Oncology
[5] Geneseeq Research Institute,Department of Medical Oncology
[6] Nanjing Geneseeq Technology Inc.,undefined
[7] Affiliated Hospital of Nantong University,undefined
[8] Qilu Hospital of Shandong University,undefined
[9] Fujian Medical University Union Hospital,undefined
来源：
Journal of Translational Medicine | / 20卷
关键词：
rearrangement; NSCLC; EGFR-TKI; Noncanonical ; fusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    CANCERS, 2019, 11 (07)
  • [12] Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Salazar, Maria F.
    Magri, Ignacio
    Pettineo, Giuseppe
    Benecchi, Sara
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (03) : 413 - 424
  • [13] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Woo, Hyun Sun
    Ahn, Hee Kyung
    Lee, Ha Yeon
    Park, Inkeun
    Kim, Young Saing
    Hong, Junshik
    Sym, Sun Jin
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    Cho, Eun Kyung
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1311 - 1315
  • [14] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Hyun Sun Woo
    Hee Kyung Ahn
    Ha Yeon Lee
    Inkeun Park
    Young Saing Kim
    Junshik Hong
    Sun Jin Sym
    Jinny Park
    Jae Hoon Lee
    Dong Bok Shin
    Eun Kyung Cho
    Investigational New Drugs, 2014, 32 : 1311 - 1315
  • [15] Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Takashima, Yuta
    Sakakibara-Konishi, Jun
    Hatanaka, Yutaka
    Hatanaka, Kanako C.
    Ohhara, Yoshihito
    Oizumi, Satoshi
    Hida, Yasuhiro
    Kaga, Kichizo
    Kinoshita, Ichiro
    Dosaka-Akita, Hirotoshi
    Matsuno, Yoshihiro
    Nishimura, Masaharu
    CLINICAL LUNG CANCER, 2018, 19 (04) : 352 - +
  • [16] GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer
    Park, Jaewoo
    Purushothaman, Baskaran
    Hong, Sera
    Choi, Munkyung
    Jegal, Kyung Hwan
    Park, Miso
    Song, Joon Myong
    Kang, Keon Wook
    LIFE SCIENCES, 2024, 348
  • [17] AFATINIB IN EGFR MUTANT NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR-TKIS
    Cappuzzo, Federico
    Tiseo, Marcello
    Chiari, Rita
    Landi, Lorenza
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Facchi-Netti, Francesco
    Levra, Matteo Giaj
    Vari, Sabrina
    Crino, Lucio
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S610 - S610
  • [18] Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
    Hirsh, Vera
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [19] A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
    Hirsh, V.
    Melosky, B.
    Goss, G.
    Morris, D.
    Morzycki, W.
    CURRENT ONCOLOGY, 2012, 19 (02) : 78 - 90
  • [20] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
12345